Date receipt dossier
EudraCT number
2004-000464-28
Company / Sponsor
Ark Therapeutics Ltd
Phase
III
Treated organism
Humans
Indication category
Cancer therapy
Disease
Operable high-grade glioma
Therapeutic approach
Suicide gene/ pro drug
Genetic modification
Thymidine Kinase (HSV-TK1)
Method of transfer of nucleic acid of interest
Human Adenovirus serotype 5
Administered biological material
Recombinant Adenovirus D (E1, E3)
Route of administration
Intratumoral
Locations in Belgium
Academisch Ziekenhuis - Vrije Universiteit Brussel;
Cliniques Universitaires de Bruxelles - Hôpital Erasme;
Centre Hospitalier Universitaire de Liège.
Cliniques Universitaires de Bruxelles - Hôpital Erasme;
Centre Hospitalier Universitaire de Liège.
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
Protocol 904